Coral Laboratories [CORALAB] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Coral Laboratories
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Coral Laboratories wins in 12 metrics, Aarti Drugs wins in 8 metrics, with 0 ties. Coral Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Coral Laboratories | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 7.14 | 23.75 | Coral Laboratories |
| Price-to-Book Ratio | 0.86 | 3.28 | Coral Laboratories |
| Debt-to-Equity Ratio | 1.77 | 44.92 | Coral Laboratories |
| PEG Ratio | 8.30 | 0.37 | Aarti Drugs |
| EV/EBITDA | 3.87 | 17.15 | Coral Laboratories |
| Profit Margin (TTM) | 17.54% | 7.80% | Coral Laboratories |
| Operating Margin (TTM) | 9.19% | 10.11% | Aarti Drugs |
| EBITDA Margin (TTM) | 9.19% | 10.11% | Aarti Drugs |
| Return on Equity | 12.01% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 10.53% | 6.53% | Coral Laboratories |
| Free Cash Flow (TTM) | $-41.67M | $674.20M | Aarti Drugs |
| Dividend Yield | 0.34% | 0.22% | Coral Laboratories |
| 1-Year Return | -46.90% | -12.97% | Aarti Drugs |
| Price-to-Sales Ratio (TTM) | 1.69 | 1.85 | Coral Laboratories |
| Enterprise Value | $685.43M | $50.72B | Aarti Drugs |
| EV/Revenue Ratio | 0.67 | 2.09 | Coral Laboratories |
| Gross Profit Margin (TTM) | 48.21% | 36.77% | Coral Laboratories |
| Revenue per Share (TTM) | $286 | $265 | Coral Laboratories |
| Earnings per Share (Diluted) | $67.61 | $20.66 | Coral Laboratories |
| Beta (Stock Volatility) | 0.68 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Coral Laboratories vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Coral Laboratories | -0.56% | -13.11% | -17.08% | -34.91% | -38.74% | -40.76% |
| Aarti Drugs | -2.51% | 0.27% | -9.96% | 2.11% | 28.03% | 7.74% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Coral Laboratories | -46.90% | 89.29% | 59.31% | -5.81% | 363.91% | 383.43% |
| Aarti Drugs | -12.97% | 12.03% | -33.03% | 242.63% | 2,725.27% | 2,466.68% |
Performance & Financial Health Analysis: Coral Laboratories vs Aarti Drugs
| Metric | CORALAB | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.72B | ₹44.80B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,320 | 150,557 |
| 90 Day Avg. Volume | 1,350 | 593,779 |
| Last Close | ₹480.00 | ₹478.45 |
| 52 Week Range | ₹471.00 - ₹999.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -51.95% | -24.65% |
| All-Time High | ₹1,190.00 (Jul 24, 2017) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -59.66% | -53.41% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.41% | 0.06% |
| Quarterly Earnings Growth | -0.71% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.08% |
| Operating Margin (TTM) | 0.09% | 0.10% |
| Return on Equity (TTM) | 0.12% | 0.12% |
| Debt to Equity (MRQ) | 1.77 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹562.96 | ₹149.84 |
| Cash per Share (MRQ) | ₹300.75 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹106.44M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹241.56M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.34% | 0.22% |
| Last 12-Month Dividend | ₹2.00 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Coral Laboratories vs Aarti Drugs
| Metric | CORALAB | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 7.14 | 23.75 |
| Forward P/E | 8.30 | 14.98 |
| PEG Ratio | 8.30 | 0.37 |
| Price to Sales (TTM) | 1.69 | 1.85 |
| Price to Book (MRQ) | 0.86 | 3.28 |
| Market Capitalization | ||
| Market Capitalization | ₹1.72B | ₹44.80B |
| Enterprise Value | ₹685.43M | ₹50.72B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.67 | 2.09 |
| Enterprise to EBITDA | 3.87 | 17.15 |
| Risk & Other Metrics | ||
| Beta | 0.68 | 0.21 |
| Book Value per Share (MRQ) | ₹562.96 | ₹149.84 |
Financial Statements Comparison: Coral Laboratories vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CORALAB | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹281.35M | ₹6.77B |
| Cost of Goods Sold | ₹145.71M | ₹4.37B |
| Gross Profit | ₹135.64M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹21.79M | ₹784.50M |
| EBITDA | ₹51.66M | ₹951.90M |
| Pre-Tax Income | ₹38.52M | ₹711.50M |
| Income Tax | ₹10.25M | ₹83.80M |
| Net Income (Profit) | ₹28.27M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CORALAB | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹34.06M | ₹45.80M |
| Total Current Assets | ₹1.77B | ₹13.38B |
| Total Current Liabilities | ₹249.58M | ₹8.37B |
| Long-Term Debt | ₹0 | ₹2.86B |
| Total Shareholders Equity | ₹2.01B | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹217.44M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CORALAB | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CORALAB | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 2,320 | 150,557 |
| Average Daily Volume (90 Day) | 1,350 | 593,779 |
| Shares Outstanding | 3.57M | 91.27M |
| Float Shares | 806,826 | 35.46M |
| % Held by Insiders | 0.78% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Coral Laboratories vs Aarti Drugs
| Metric | CORALAB | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹2.00 | ₹1.00 |
| Last 12-Month Dividend Yield | 0.34% | 0.22% |
| 3-Year Avg Annual Dividend | ₹0.67 | ₹1.00 |
| 3-Year Avg Dividend Yield | 0.22% | 0.23% |
| 3-Year Total Dividends | ₹2.00 | ₹3.00 |
| Ex-Dividend Date | Sep 20, 2024 | Feb 04, 2025 |